ALTTO Disappoints Clinicians and Upends ResearchALTTO Disappoints Clinicians and Upends Research

Adding lapatinib to trastuzumab does not improve outcomes in the adjuvant setting, in contrast to what was seen in the neoadjuvant setting. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news